Section Arrow
EXEL.NASDAQ
- Exelixis
Quotes are at least 15-min delayed:2024/06/07 21:16 EDT
Last
 21.88
-0.3 (-1.35%)
Day High 
22.17 
Prev. Close
22.18 
1-M High
22.41 
Volume 
1.30M 
Bid
21.25
Ask
22.5
Day Low
21.86 
Open
22.16 
1-M Low
20.14 
Market Cap 
6.46B 
Currency USD 
P/E 34.12 
%Yield
10-SMA 21.21 
20-SMA 21.19 
50-SMA 22.28 
52-W High 24.34 
52-W Low 18.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.65/1.57
Enterprise Value
6.65B
Balance Sheet
Book Value Per Share
7.31
Cash Flow
Cash Flow Yield
0.05
Income Statement
Total Revenue
1.83B
Operating Revenue Per Share
6.09
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GERNGeron Corp4.59+0.7+17.99%-- 
DNAGinkgo Bioworks Holdings0.5141-0.0359-6.53%-- 
NVAXNovavax18.17-1.385-7.08%-- 
MCRBSeres Therapeutics0.614-0.2391-28.03%-- 
BMEABiomea Fusion4.14-7.13-63.27%-- 
Quotes are at least 15-min delayed:2024/06/07 21:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.